Benchmark reiterates Sportradar stock rating on lower Q2 estimates

Benchmark reiterated a Buy on Sportradar (SRAD) with a $16.00 price target, but reduced Q2 revenue to €376.0M (from €385.5M) vs €383.8M consensus, citing slower U.S. online sports betting growth and ongoing FX pressure. It also cut Q2 adjusted EBITDA to €74.0M (from €74.9M) vs €79.5M consensus, implying a 19.7% EBITDA margin vs ~20.7% street expectations. Offsetting this, Sportradar announced a multi-year Kalshi agreement to supply official sports data, prompting UBS/Needham to maintain or raise targets (UBS $30; Needham $23), supporting the view that the stock is undervalued despite near-term headwinds.

Analysis

Near term, this is a margin-quality story, not a top-line story. The estimate cut signals that high-volume betting activity is not translating cleanly into fee capture, which usually keeps the multiple compressed until management proves the conversion can re-accelerate. Because the stock is already de-rated, the downside is less about another small EPS miss and more about a second-cut to full-year margin guidance or a sustained FX drag that prevents leverage from showing up in 2H.

The real second-order effect is the prediction-market optionality. If that channel scales, it is a different revenue mix than traditional sportsbook data: more recurring, less dependent on sportsbook hold, and potentially better valued by the market. But that monetization path is slow and policy-sensitive, so the press-release value is likely ahead of the cash-flow value by at least 6-12 months.

Consensus may be too focused on the current quarter and underestimating how quickly the market could rerate SRAD if it demonstrates even modest attached revenue from prediction markets. The contrarian risk is that investors are paying for optionality before there is evidence of contribution, which makes the setup vulnerable to a flat or slightly weak print. Falsifier: if quarterly EBITDA margin holds near/above 20.5% and management quantifies meaningful 2H prediction-market revenue, the stock can grind toward the low-$20s; if not, the name likely stays range-bound below the current target.

Key Decisions for Investors

• No fresh long into earnings; wait for the next print to confirm whether the estimate cut was one-off noise or the start of a slower monetization trend. Best entry is only after management restores confidence on EBITDA conversion.
• If you want exposure to prediction-market optionality, use a defined-risk call spread in SRAD over the next 3-6 months rather than common stock; the thesis needs proof, not just a partnership headline.
• Trade SRAD as a relative-value long only if the next update shows revenue from prediction markets; otherwise treat rallies toward $16 as sellable until the margin path reaccelerates.
• Set an alert on Q2 EBITDA margin and full-year guidance: a move below ~20% margin or another guidance cut would invalidate the bull case and argue for a short-term defensive stance.